Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

CANCER:

Osteosarcoma

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related cancers:

No biomarker	Osteosarcoma	No biomarker	Osteosarcoma	doxorubicin hydrochloride Sensitive: A1 - Approval doxorubicin hydrochloride Sensitive : A1	doxorubicin hydrochloride Sensitive: A1 - Approval doxorubicin hydrochloride Sensitive : A1
No biomarker	Osteosarcoma	No biomarker	Osteosarcoma	methotrexate Sensitive: A1 - Approval methotrexate Sensitive : A1	methotrexate Sensitive: A1 - Approval methotrexate Sensitive : A1
No biomarker	Osteosarcoma	No biomarker	Osteosarcoma	regorafenib Sensitive: A2 - Guideline regorafenib Sensitive : A2	regorafenib Sensitive: A2 - Guideline regorafenib Sensitive : A2
No biomarker	Osteosarcoma	No biomarker	Osteosarcoma	Sensitive: A2 - Guideline Sensitive : A2	Sensitive: A2 - Guideline Sensitive : A2
No biomarker	Osteosarcoma	No biomarker	Osteosarcoma	gemcitabine + docetaxel + cyclophosphamide Sensitive: A2 - Guideline gemcitabine + docetaxel + cyclophosphamide Sensitive : A2	gemcitabine + docetaxel + cyclophosphamide Sensitive: A2 - Guideline gemcitabine + docetaxel + cyclophosphamide Sensitive : A2
No biomarker	Osteosarcoma	No biomarker	Osteosarcoma	carboplatin + cyclophosphamide + etoposide IV Sensitive: A2 - Guideline carboplatin + cyclophosphamide + etoposide IV Sensitive : A2	carboplatin + cyclophosphamide + etoposide IV Sensitive: A2 - Guideline carboplatin + cyclophosphamide + etoposide IV Sensitive : A2
No biomarker	Osteosarcoma	No biomarker	Osteosarcoma	carboplatin + cyclophosphamide Sensitive: A2 - Guideline carboplatin + cyclophosphamide Sensitive : A2	carboplatin + cyclophosphamide Sensitive: A2 - Guideline carboplatin + cyclophosphamide Sensitive : A2
No biomarker	Osteosarcoma	No biomarker	Osteosarcoma	cyclophosphamide + etoposide IV Sensitive: A2 - Guideline cyclophosphamide + etoposide IV Sensitive : A2	cyclophosphamide + etoposide IV Sensitive: A2 - Guideline cyclophosphamide + etoposide IV Sensitive : A2
No biomarker	Osteosarcoma	No biomarker	Osteosarcoma	gemcitabine + docetaxel + ifosfamide Sensitive: A2 - Guideline gemcitabine + docetaxel + ifosfamide Sensitive : A2	gemcitabine + docetaxel + ifosfamide Sensitive: A2 - Guideline gemcitabine + docetaxel + ifosfamide Sensitive : A2
No biomarker	Osteosarcoma	No biomarker	Osteosarcoma	carboplatin + ifosfamide + etoposide IV Sensitive: A2 - Guideline carboplatin + ifosfamide + etoposide IV Sensitive : A2	carboplatin + ifosfamide + etoposide IV Sensitive: A2 - Guideline carboplatin + ifosfamide + etoposide IV Sensitive : A2
No biomarker	Osteosarcoma	No biomarker	Osteosarcoma	carboplatin + ifosfamide Sensitive: A2 - Guideline carboplatin + ifosfamide Sensitive : A2	carboplatin + ifosfamide Sensitive: A2 - Guideline carboplatin + ifosfamide Sensitive : A2
No biomarker	Osteosarcoma	No biomarker	Osteosarcoma	cisplatin + doxorubicin hydrochloride + ifosfamide + methotrexate Sensitive: A2 - Guideline cisplatin + doxorubicin hydrochloride + ifosfamide + methotrexate Sensitive : A2	cisplatin + doxorubicin hydrochloride + ifosfamide + methotrexate Sensitive: A2 - Guideline cisplatin + doxorubicin hydrochloride + ifosfamide + methotrexate Sensitive : A2